Abaloparatide Treatment for Osteoporosis
Patient Selection and Treatment Considerations
- High-risk patients, including those with a history of osteoporotic fracture, particularly hip or vertebral, should be considered for abaloparatide treatment, as recommended by the American College of Physicians, based on evidence from Arthritis and Rheumatology 1
- Patients with multiple risk factors for fracture should also be considered for abaloparatide treatment, according to the American College of Physicians guideline, based on evidence from Annals of Internal Medicine 2
- Women of childbearing potential must use effective birth control during abaloparatide treatment, due to lacking safety data in pregnancy, as noted in Arthritis and Rheumatology 1
- The American College of Physicians guideline notes that clinicians should be aware of potential adverse cardiovascular effects, such as palpitations and increased heart rate, which occur more frequently with abaloparatide than with teriparatide, as reported in Annals of Internal Medicine 2
Treatment Duration and Sequential Therapy
- After completing abaloparatide treatment, patients must transition to an antiresorptive agent, such as a bisphosphonate or denosumab, to maintain bone mineral density gains and prevent rebound bone loss, as recommended by the American College of Physicians, based on evidence from Annals of Internal Medicine 2 and Arthritis and Rheumatology 1
Adverse Effects
- Common adverse effects in postmenopausal women include hypercalciuria, dizziness, nausea, headache, fatigue, upper abdominal pain, and vertigo, as reported in Praxis Medical Insights: Practical Summaries of Clinical Guidelines 3
- Common adverse effects in men include bone pain, as reported in Annals of Internal Medicine 2
Clinical Advantages
- Abaloparatide has a more favorable profile than teriparatide due to its maintained anabolic window without increased resorption over time, as noted in Annals of Internal Medicine 2
Transition to Antiresorptive Therapy After Tymlos (Abaloparatide)
Rationale for Sequential Therapy
- Patients completing a course of Tymlos should be switched immediately to an anti‑resorptive agent (e.g., bisphosphonate or denosumab) to avert rapid bone loss and rebound vertebral fractures; discontinuation without such follow‑up therapy has been linked to a high risk of multiple vertebral fractures as early as 7–9 months after the last Tymlos dose. 4